All In Biotech

Drug Trial Radar · NCT06472245

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 363 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

363

Planned (sponsor's estimate)

Start

Dec 3, 2024

Primary completion

May 1, 2028

Study completion Dec 15, 2028

Sponsor

Lead sponsor
OSE ImmunotherapeuticsIndustry
Sponsor type
Industry
Collaborators
Exystat; GeneDx
First posted
Jun 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).

Conditions

  • Patients With Non-Small Cell Lung Cancer

Interventions

  • OSE2101Drug

    OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.

  • DocetaxelDrug

    Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.

  • NGS HLAA2 assayDevice

    Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OS defined as time from randomization to deathTime frame: From randomization date through study completion, an average of 3 years

Locations

207 sites in 14 countries. Site status is shown where the registry gives one.

  • Clinical Research Advisors, LLC

    Beverly Hills, California · Recruiting

  • Clinical Research Advisors - Encino

    Encino, California · Active not recruiting

  • Clinical Research Advisors - West Hollywood

    Los Angeles, California · Active not recruiting

  • Clinical Research Advisors - Korea Town

    Los Angeles, California · Active not recruiting

  • SCL Health - Saint Joseph Hospital Cancer Center

    Littleton, Colorado · Withdrawn

  • Lutheran Medical Center - Cancer Centers of Colorado

    Wheat Ridge, Colorado · Recruiting

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut · Recruiting

  • Georgetown Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Comprehensive Hematology Oncology - Bradenton Clinic

    Bradenton, Florida · Active not recruiting

  • Comprehensive Hematology Oncology - Brandon Clinic

    Brandon, Florida · Active not recruiting

  • Cancer Specialists of North Florida - Fleming Island

    Fleming Island, Florida · Recruiting

  • Cancer Specialists of North Florida - Riverside

    Jacksonville, Florida · Recruiting

  • Cancer Specialists of North Florida Southside

    Jacksonville, Florida · Recruiting

  • Cancer Specialists of North Florida - Northside

    Jacksonville, Florida · Recruiting

  • Cancer Specialists of North Florida - Southpoint

    Jacksonville, Florida · Recruiting

  • Cancer Specialists of North Florida - Baptist South

    Jacksonville, Florida · Active not recruiting

  • Cancer Specialists of North Florida

    Jacksonville Beach, Florida · Recruiting

  • Comprehensive Hematology Oncology - Largo Clinic

    Largo, Florida · Active not recruiting

  • Cancer Specialists of North Florida - Beaches

    Neptune Beach, Florida · Active not recruiting

  • Comprehensive Hematology Oncology - Palm Harbor Clinic

    Palm Harbor, Florida · Active not recruiting

  • Cancer Specialists Of North Florida - St. Augustine

    Saint Augustine, Florida · Recruiting

  • Comprehensive Hematology Oncology - Bayfront Clinic

    St. Petersburg, Florida · Active not recruiting

  • Comprehensive Hematology Oncology

    St. Petersburg, Florida · Recruiting

  • Comprehensive Hematology Oncology - Trinity Clinic

    Trinity, Florida · Recruiting

  • University of Illinois Cancer Center

    Chicago, Illinois · Recruiting

  • Alliance for Multispecialty Research (AMR) - Kansas City Oncology

    Merriam, Kansas · Withdrawn

  • Mary Bird Perkins Cancer Center - Baton Rouge

    Baton Rouge, Louisiana · Active not recruiting

  • Pontchartrain Cancer Center - Covington Office

    Covington, Louisiana · Recruiting

  • Pontchartrain Cancer Center - Hammond Office

    Hammond, Louisiana · Recruiting

  • Ascension Saint Agnes Hospital

    Baltimore, Maryland · Recruiting

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts · Recruiting

  • Nebraska Hematology-Oncology - Revive Research Institute LLC

    Lincoln, Nebraska · Recruiting

  • New York Cancer & Blood Specialists - Babylon Medical Oncology

    Babylon, New York · Active not recruiting

  • Optum Medical Care - Carmel/Brewster Campus

    Brewster, New York · Terminated

  • Brooklyn Radiation Oncology

    Brooklyn, New York · Terminated

  • Optum Medical Care - Fishkill Westage Campus

    Fishkill, New York · Terminated

  • Clinical Research Alliance

    Lake Success, New York · Terminated

  • Optum Medical Care - Mount Kisco Campus 90

    Mount Kisco, New York · Terminated

  • New York Cancer & Blood Specialists - New Hyde Park

    New Hyde Park, New York · Recruiting

  • Optum Hematology Oncology - Lake Success

    New Hyde Park, New York · Terminated

Showing 40 of 207 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.